Αρχική World News FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma World News FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma Από Ogkologos - 6 Ιουνίου, 2025 846 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Cancer.Net’s 20th Anniversary: Celebrating Our Mission of Providing Trustworthy Cancer Information 17 Μαΐου, 2022 How Receiving My Own Cancer Diagnosis Changed My Perspective on Caring... 25 Αυγούστου, 2020 How My Cancer Diagnosis Has Fueled My Work in Improving Access... 19 Δεκεμβρίου, 2023 Cancer Patients Have Been Lonelier During the COVID-19 Pandemic 27 Μαΐου, 2021 Φόρτωση περισσοτέρων HOT NEWS AI is impacting cancer care, but also the environment Can cancer cells communicate? FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line...